CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: May 13, 2021
Result type: Reports
Project Number: SR0661-000
Product Line: Reimbursement Review

Generic Name: risdiplam

Brand Name: Evrysdi

Manufacturer: Hoffmann La-Roche Ltd.

Therapeutic Area: Spinal muscular atrophy

Indications: ​For the treatment of spinal muscular atrophy (SMA) in patients 2 months and older.

Manufacturer Requested Reimbursement Criteria1: For the treatment of spinal muscular atrophy (SMA) in patients 2 months and older.

Submission Type: Initial

NOC Status at Filing: Pre NOC

Project Status: Active

Companion Diagnostics: No

Fee Schedule: Schedule A

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Submit Feedback

Key Milestones2

Call for patient/clinician input open October 22, 2020
Call for patient/clinician input closed December 10, 2020

- Patient input submission received from Cure SMA Canada and Muscular Dystrophy Canada

Submission received November 19, 2020
Submission accepted December 03, 2020
Review initiated December 04, 2020
Draft CADTH review report(s) provided to sponsor for comment March 08, 2021
Deadline for sponsors comments March 17, 2021
CADTH responses on draft review report(s) provided to sponsor April 09, 2021
Expert committee meeting (initial) April 21, 2021
Draft recommendation issued to sponsor May 05, 2021
Draft recommendation posted for stakeholder feedback May 13, 2021
End of feedback period May 28, 2021